Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals completed its previously announced merger with Supernus Pharmaceuticals, with the combined entity renamed Supernus, Inc. (Nasdaq: SUPN). To fund a $1.0 billion special cash dividend to legacy Indivior stockholders, the company entered into a $650 million senior secured term loan facility with Citibank.
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior reported record Q3 2026 financial results while providing a status update on its pending all-stock merger of equals with Supernus Pharmaceuticals. The merger, which has received shareholder approval, is expected to close on November 2, 2026, with the combined company operating as Supernus, Inc. (ticker: SUPN).
Counterparty
Supernus Pharmaceuticals, Inc.
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda. Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda.”
Joe Ciaffoni, Chief Executive Officer
“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year.”